(S)-2-mercapto-4-methylpentanoic acid | 66386-08-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (S)-2-mercapto-4-methylpentanoic acid
• 英文别名: (S)-2-Mercapto-4-methyl-valeriansaeure；(S)-2-mercapto-4-methyl-valeric acid；L-Thioleucinsaeure；(2S)-4-Methyl-2-sulfanylpentanoic acid
• CAS: 66386-08-1
• 化学式: C₆H₁₂O₂S
• 分子量: 148.226
• InChiKey: VOKMUKPTVFXIMU-YFKPBYRVSA-N

物化性质

• 沸点：
  236.1±23.0 °C(Predicted)
• 密度：
  1.081±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  38.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-2-mercapto-4-methylpentanoic acid 在 盐酸 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 对甲苯磺酸 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 氯仿 为溶剂， 反应 22.0h， 生成 4-{(S)-2-((S)-2-tert-Butoxycarbonylamino-3-phenyl-propionylamino)-2-[(1S,2R)-1-cyclohexylmethyl-3-((S)-1-ethoxycarbonyl-3-methyl-butylsulfanyl)-2-hydroxy-propylcarbamoyl]-ethyl}-imidazole-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Inhibitors of human renin with C-termini derived from amides and esters of .alpha.-mercaptoalkanoic acids

  摘要：

  New transition-state analogues bearing C-termini derived from alpha-mercaptoalkanoic acids, esters, and amides were prepared and evaluated as inhibitors of human renin. Addition of alpha-mercaptoalkanoate esters to a chiral Boc-amino epoxide intermediate led ultimately to the target [(2R,3S)-3-(BocPheHis-amino)-4-cyclohexyl-2-hydroxy-1-butyl]thio derivatives. The corresponding sulfoxide and sulfone analogues were also investigated. Some of these derivatives, including one with a stable BocPhe replacement, were relatively potent inhibitors of human plasma renin, having IC50 values below 10 nM. When selected compounds were administered intravenously to sodium-deficient rhesus monkeys (Macaca mulatta) at 0.06-1 mg/kg, they reduced plasma renin activity by 87-94%. However, the accompanying drop in blood pressure was of short duration.

  DOI：

  10.1021/jm00093a009
• 作为产物：
  描述：

  D-亮氨酸 在 nitrosyl bromide 作用下， 生成 (S)-2-mercapto-4-methylpentanoic acid
  参考文献：
  名称：

  Peptide-gap inhibitors. 2. Stereoselective synthesis of enantiomeric dipeptide analogs of glycylleucine which contain methylene thioether groups substituted for peptide linkages

  摘要：

  DOI：

  10.1021/jo00402a044

文献信息

• Dual-acting benzoimidazole antihypertensive agents
  申请人：Allegretti Paul

  公开号：US20080318951A1

  公开（公告）日：2008-12-25

  The invention is directed to compounds having the formula: wherein: Ar, r, n, X, R 2-3 and R 5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  这项发明涉及具有以下结构的化合物： 其中：Ar、r、n、X、R 2-3 和R 5-7 如规范中所定义，并且其药学上可接受的盐。这些化合物具有AT 1 受体拮抗活性和神经肽酶抑制活性。该发明还涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• Dual-acting antihypertensive agents
  申请人：Allegretti Paul

  公开号：US20080269305A1

  公开（公告）日：2008-10-30

  The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R 5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

  该发明涉及具有以下公式的化合物：其中：Ar、r、Y、Z、Q、W、X和R5-7如规范中定义，并且其药学上可接受的盐。这些化合物具有AT1受体拮抗活性和神经肽酶抑制活性。该发明还涉及包含这些化合物的药物组合物；使用这些化合物的方法；以及制备这些化合物的过程和中间体。
• Synthesis and determination of enantiomeric excesses of non-racemic tert-thiols derived from chiral secondary α-mercaptocarboxylic acids
  作者：Bert Strijtveen、Richard M. Kellogg

  DOI：10.1016/s0040-4020(01)87682-1

  日期：1987.1

  optically active without employment of a chiral auxiliary. Their enantiomeric excesses were determined by esterification, conversion to diasterecomeric phosphonodithioates on reaction with-31CH3-POCl2, followed by integration of the well separated proton-decoupled P NMR signals. This is apparently the first example of enantiomeric excess determinations of chiral tertiary thiols.

  已经制备了丙酸，3-苯基丙酸，2-苯基乙酸，3-甲基丁酸，4-甲基戊酸和（S）-3-甲基戊酸的旋光α-巯基衍生物。这些酸与新戊醛缩合得到2-叔丁基-5-取代的1,3-氧杂硫杂环戊酮（）；的形成在过量几何异构体并获得通过结晶纯。对于5-苄基衍生物（），主要的非对映异构体的排列通过X射线晶体学确定。这些-二取代的杂环（），在用二异丙基丙酰胺锂（LDA）或六甲基二硅叠氮化锂（LHMDS）进行质子化后，随后与亲电子试剂如卤代烷，醛或酮的亲电反应，在水解后以高对映体过量的形式提供α-支链的α-巯基羧酸或酯（）。这些是由于α-位置上的质子被羰基整体取代而保持构型且没有外消旋作用。该立体化学过程是通过晶体结构确定（2S）-的方法确定的（2S）-是由-5-苯基-1,3-氧杂噻喃-4-酮（）。无需使用手性助剂即可获得具有光学活性的叔α-巯基羧酸。通过酯化，与31 CH 3 -POCl 2反应转化为非对映体膦
• Structure-activity relationship of leucyladenylate sulfamate analogues as leucyl-tRNA synthetase (LRS)-targeting inhibitors of Mammalian target of rapamycin complex 1 (mTORC1)
  作者：Suyoung Yoon、Sung-Eun Kim、Jong Hyun Kim、Ina Yoon、Phuong-Thao Tran、Jihyae Ann、Changhoon Kim、Woong Sub Byun、Sangkook Lee、Sunghoon Kim、Jiyoun Lee、Jeewoo Lee

  DOI：10.1016/j.bmc.2019.01.037

  日期：2019.3

  Leucyl-tRNA synthetase (LRS) plays an important role in amino acid-dependent mTORC1 signaling, which is known to be associated with cellular metabolism and proliferation. Therefore, LRS-targeting small molecules that can suppress mTORC1 activation may provide an alternative strategy to current anticancer therapy. In this work, we developed a library of leucyladenylate sulfate analogues by extensively

  Leucyl-tRNA合成酶（LRS）在氨基酸依赖性mTORC1信号传导中起重要作用，已知该信号与细胞代谢和增殖有关。因此，可以抑制mTORC1激活的靶向LRS的小分子可以为当前的抗癌治疗提供替代策略。在这项工作中，我们通过广泛修饰包括腺嘌呤，核糖和亮氨酸的三个不同药效学区域，开发了硫酸亮环烯丙酸酯类似物的文库。通过基于细胞的mTORC1活化分析鉴定了几种有效的化合物，并进一步测试了其抗癌活性。选定的化合物大部分对五种不同的癌细胞系表现出选择性的细胞毒性，支持以下假设：LRS介导的mTORC1途径是当前治疗方法的有希望的替代靶点。
• Renin inhibitors containing the
  申请人：Merck & Co., Inc.

  公开号：US05114925A1

  公开（公告）日：1992-05-19

  Compounds of the formula: ##STR1## which are potent inhibitors of human renin and are useful for treating various forms of renin-associated hypertension, hyperaldosteronism and congestive heart failure; compositions containing these renin-inhibitory compounds, optionally with other antihypertensive agents; and methods of treating hypertension, hyperaldosteronism or congestive heart failure or of establishing renin as a causative factor in these conditions which employ these novel compounds.

  这是一段关于某种化合物的说明，化合物的化学式为：##STR1## 这些化合物是人类肾素的强效抑制剂，可用于治疗各种形式的肾素相关高血压、高醛固酮症和充血性心力衰竭；含有这些肾素抑制剂化合物的组合物，可选搭配其他降压剂；以及使用这些新型化合物治疗高血压、高醛固酮症或充血性心力衰竭，或将肾素作为这些疾病的病因因素的方法。